🧬 Pharma's Coordination Tax & the 2 Paths That Could Actually Disrupt It | Alex Telford (3/4)
June 8, 2026
In this episode, Jon Chee sits down with Alex Telford, founder of Convoke, to examine why large pharma resists AI transformation. Drawing on seven years at Charles River Associates, Alex maps the coordination tax of siloed orgs, the tacit knowledge lost when experts retire, and why software efficiency is the wrong axis to compete on. His frame: factory electrification — the gains don't arrive until you redesign the whole org around the technology.
🧬 The Biotech Startups Podcast is powered by Excedr—helping life science startups accelerate R&D and commercialization with founder-friendly equipment leasing. Skip the upfront costs, stay lean, and focus on breakthrough science.
As a TBSP listener, you can get exclusive perks through Excedr's partner network—special savings, promotions, and more. Explore these offers today: https://www.excedr.com/partners.
"No. I do think you do need to recreate the orchestration. I think you have to retool the organization around these new technologies, and some will not be able to rearchitecture, and they will die. Some will be able to rearchitecture and they will thrive."
"No. I do think you do need to recreate the orchestration. I think you have to retool the organization around these new technologies, and some will not be able to rearchitecture, and they will die. Some will be able to rearchitecture and they will thrive."
In this episode, Jon Chee sits down with Alex Telford, founder of Convoke, to examine why large pharma resists AI transformation. Drawing on seven years at Charles River Associates, Alex maps the coordination tax of siloed orgs, the tacit knowledge lost when experts retire, and why software efficiency is the wrong axis to compete on. His frame: factory electrification — the gains don't arrive until you redesign the whole org around the technology.
Key Topics Covered:
- Re-architecting Around General-Purpose Technology: Why pharma's AI gains won't arrive until the org is redesigned around it.
- The Tacit Knowledge Problem: Why decades of regulatory expertise walks out the door when a scientist retires.
- The Two Paths That Could Disrupt Pharma: Why differentiated target discovery or vertically integrated DTC beat competing on software efficiency.
- LillyDirect and the Consumer Health Bundle: How Eli Lilly's DTC platform hints at a new pharma business model.
- Signal-to-Noise Beats Raw Data: Why more data often makes LLM systems worse, and what Renaissance Technologies' data-cleaning edge was actually about.
- Writing in Public Built a Company: How a blog post led to a podcast, a cofounder email, and Convoke's $8.6M seed round.
If you enjoy The Biotech Startups Podcast, please consider subscribing, leaving a review, or sharing it with your friends. Thanks for listening.
Links:
Subscribe to the Podcast:
Apple: https://podcasts.apple.com/us/podcast/the-biotech-startups-podcast/id1679591994
Spotify: https://open.spotify.com/show/2PSL162R2s0zOwU5913Zv4
Youtube: https://www.youtube.com/@thebiotechstartupspodcast
Website: https://www.thebiotechstartupspodcast.com/
Find our guest, Alex Telford at these links:
LinkedIn: https://www.linkedin.com/in/alexander-telford/
Website: https://www.convoke.bio/
Find our host, Jon Chee, at these links:
LinkedIn: https://www.linkedin.com/in/jonchee/
Learn more about Excedr:
LinkedIn: https://www.linkedin.com/company/excedr/
Website: https://www.excedr.com
Intro & Outro Songs Created by OkKyojin, Owned by Excedr:
Website: https://flow.page/kyojin
Resources & Articles:
The Dynamo and the Computer — Paul David on electrification and the productivity paradox: https://www.almendron.com/tribuna/wp-content/uploads/2018/03/the-dynamo-and-the-computer-an-historical-perspective-on-the-modern-productivity-paradox.pdf
General-Purpose Technologies (Wikipedia): https://en.wikipedia.org/wiki/General-purpose_technology
King – Man + Woman = Queen: The Mathematics of Computational Linguistics: https://www.technologyreview.com/2015/09/17/166211/king-man-woman-queen-the-marvelous-mathematics-of-computational-linguistics/
Convoke Raises $8.6M to Build the AI OS for Biopharma: https://www.convoke.bio/blog/announcing-our-seed-fundraise
Pfizer and Lilly Move Into Direct-to-Consumer Pharma: https://www.biopharmadive.com/news/pfizer-eli-lilly-direct-to-consumer-glp-1/716866/
Companies, Universities, & People Mentioned:
Convoke: https://www.convoke.bio/
Charles River Associates (CRA): https://www.crai.com
Alnylam Pharmaceuticals: https://www.alnylam.com
BioMarin Pharmaceutical: https://www.biomarin.com
Eli Lilly: https://www.lilly.com
Hims & Hers: https://www.hims.com
Renaissance Technologies: https://www.rentec.com
Bridgewater Associates: https://www.bridgewater.com
Ray Dalio: https://www.linkedin.com/in/raydalio/
Tobi Lütke: https://www.linkedin.com/in/tobiaslutke/
Timestamps:
00:00 Intro
02:12 Rearchitecting Organizations Around New Technology
04:06 Encoding Tacit Knowledge Before It Walks Out the Door
05:42 Can Large Pharma Digitize 40,000 People?
08:23 Target Discovery and DTC: The Two Real Paths to Disruption
11:40 LillyDirect and the Vertically Integrated Pharma Model
11:59 Remote-First Orgs and the Tacit Knowledge Advantage
13:13 Signal-to-Noise Beats Raw Data Every Time
16:10 The Data Cleaning Mandate Nobody Wants to Do
18:04 The Vibe-Coding Mania and Disposable Software Trap
20:45 From NLP Curiosity to Founding Convoke
23:55 How Writing in Public Nucleated the Company
The Biotech Startups Podcast gives you a front-row seat to the business and science of building a biotech. Hosted by Jon Chee, CEO of Excedr, the show features honest conversations with founders, execs, and investors about their work, their companies, and how they got there. From scientific breakthroughs to startup lessons, each episode explores what it really takes to grow a life science company—from pre-seed to IPO.